Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11611150 | 0.90 | ALOX5 (0.35) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL32688597 | 0.89 | ALOX5 (0.47) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL2958923 | 0.87 | ALOX5 (0.46) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL11602901 | 0.86 | HSD11B1 (0.38) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL11603911 | 0.86 | MEN1 (0.45) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL10835600 | 0.82 | NPC1 (0.42) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL7529601 | 0.82 | MEN1 (0.40) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL32688715 | 0.81 | NPC1 (0.41) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL32688563 | 0.79 | NPC1 (0.41) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL11603592 | 0.79 | POLB (0.47) | MEN1NPC1RAB9AKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | OSMO LABS PBC (US) | 2026-03-19 | — | — | US | disclosed |
| US-RE37303-E1 | Imidazole compounds and their therapeutic applications | INSTITUT NATIONAL DEL LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2001-07-31 | — | — | US | disclosed |
| US-5559113-A | ANTAGONISTS TO HISTAMINE H3 RECEPTORS, SEDATIVES, ANTICONVULSANTS, ANTIULCER AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | 1996-09-24 | — | — | US | disclosed |
| US-5290790-A | Histamine H3 antagonists, psychotropic action | NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1994-03-01 | — | — | US | disclosed |
| US-4349552-A | TREATMENT OF CANCER | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1982-09-14 | — | — | US | disclosed |
| EP-0010941-B1 | 5-FLUOROURACIL DERIVATIVES, PREPARATION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-05-12 | — | — | EP | disclosed |
| EP-0010941-A1 | 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-14 | — | — | EP | disclosed |
| US-4091020-A | CONDENSATION, CATALYTIC DECARBOXYLATION | MERCK & CO., INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-4065497-A | MICROBIOCIDES, ALGICIDES | MERCK & CO., INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-4058625-A | Broad spectrum antimicrobial compositions containing tris-(hydroxymethyl)aminomethane and polyamines | MERCK & CO., INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-4035174-A | MICROBIOCIDES | MERCK & CO., INC. (US) | 1977-07-12 | — | — | US | disclosed |
| US-4033748-A | MICROBIOCIDES | MERCK & CO., INC. (US) | 1977-07-05 | — | — | US | disclosed |
| US-4003934-A | ANTIMICROBIAL AGENTS, ALGAE INHIBITORS | MERCK & CO., INC. (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | CBR1, CBR3, TAS2R1 | MEN1 3787/4885NPC1 1366/4885RAB9A 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.